Concentration pills: can they lead to addictive disorders?

The concept of “focus pills” refers to various types of stimulant-type psychotropic drugs which, in most cases, are prescribed to treat Attention Deficit Hyperactivity Disorder and narcolepsy.

However, beyond their use in the clinical context, there are those who make the consumption of these substances a habit; they are mainly students or professionals who are under high pressure situations and feel that they need to use this type of product to meet the demands of everyday life.

Those types of consumers who use the pills outside of a doctor’s instructions are particularly vulnerable to the development of addiction problems, so in many cases, in the medium term, the use of these drugs results in a health problem. In this article we will see to what extent this use of pills for concentration can trigger addictions.

    What are strength pills?

    In most cases, what is commonly understood as strength pills or study pills is a collection of oral medications that fall into two categories: methylphenidates and methamphetamines. The most famous examples of each are Ritalin and Adderall respectively.

    These are substances which have a stimulating and activating effect on the nervous system, although through different mechanisms, and are used in the face of psychological disorders such as ADHD in children (in particular methylphenidate).

    These substances mimic the functioning of certain chemicals naturally present in the human brainAnd that is why, once introduced into the body and reaching the nervous system, they begin to interact with neurons and alter their functioning; in this case, making the nerve cells highly activated and therefore with a great capacity to engage in tasks.

      The risk of dependence

      These products present very important risks to consider. First, as with all mind-altering drugs, they have side effects that, if any, may cause more harm than good. They do not always have to give, but among them the most common are:

      • arterial hypertension
      • dizziness
      • abdominal pain
      • Irregular heartbeat
      • anxiety

      In addition, other side effects that may occur and which present a higher level of danger (mainly associated with methamphetamines) are as follows:

      • convulsions
      • Stroke

      Second, these pills can lead to addictive disorder. Although the risk of this happening is relatively low if the doctor’s instructions are followed and the doses are not high, there are many people who end up becoming dependent on the self-administration of these drugs themselves (Even though accessing them without a prescription is illegal).

      In fact, as the doses are taken, the brain “gets used” to supporting its functioning in the constant presence of this drug in the functioning of its neurons, so that as the weeks go by. increasingly depend on this class of molecules introduced from the outside. Outraged, increasingly higher doses are needed to stop feeling unwell about abstinence.

      On the other hand, addiction to strength pills can occur at virtually any age, although the risk of this happening is higher in adults, given that it is relatively difficult to access.

      Are you looking for professional help with addictions?

      If you have developed a chemical or behavioral dependence and are looking for healthcare professionals who offer treatment, please contact us.

      Fr CITA clinics we specialize in the treatment of addictions, and we also provide our patients with a residential module fully equipped and equipped with all kinds of activities, located in an environment where calm and nature predominate. You can find us in Barcelona and Dosrius (Mataró).

      Bibliographical references:

      • Berman, S .; O’Neill, J .; Pors, S .; Bartzokis, G .; London, ED (2008). Abuse of amphetamines and structural abnormalities of the brain. Annals of the New York Academy of Sciences, 1141 (1): pp. 195-220.
      • Gilmore A .; Milne R. (2001). “Methylphenidate in children with hyperactivity: a review and analysis of its usefulness.” Pharmacoepidemiol Drug Saf, 10 (2): pages 85-94.
      • Kimko, HC; Cross, JT; Abernethy, DR (1999). Pharmacokinetics and clinical efficacy of methylphenidate. Clinical Pharmacokinetics, 37 (6): pages 457-470.
      • Patrick, KS; González, MA; Straughn, AB; Markowitz, JS (2005). New formulations of methylphenidate for the treatment of attention deficit hyperactivity disorder. Expert Opinion on Drug Administration, 2 (1): pages 121-43.
      • Spiller, HA; Hays, HL; Aleguas, A. (2013). Drug overdose for attention deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity and management. CNS Drugs, 27 (7): pages 531 to 554.

      Leave a Comment